ORIGIN AND PREVALENCE OF HUMAN T-LYMPHOTROPIC VIRUS TYPE 1 (HTLV-1) AND TYPE 2 (HTLV-2) AMONG INDIGENOUS POPULATIONS IN THE AMERICAS

Imagem de Miniatura
Arquivos
art_PAIVA_ORIGIN_AND_PREVALENCE_OF_HUMAN_TLYMPHOTROPIC_VIRUS_TYPE_2015.PDF (1.41 MB)
Citações na Scopus
48
Tipo de produção
article
Data de publicação
2015
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Autores
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.57, n.1, p.1-13, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Human T-lymphotropic virus type 1 (HTLV-1) is found in indigenous peoples of the Pacific Islands and the Americas, whereas type 2 (HTLV-2) is widely distributed among the indigenous peoples of the Americas, where it appears to be more prevalent than HTLV-1, and in some tribes of Central Africa. HTLV-2 is considered ancestral in the Americas and is transmitted to the general population and injection drug users from the indigenous population. In the Americas, HTLV-1 has more than one origin, being brought by immigrants in the Paleolithic period through the Bering Strait, through slave trade during the colonial period, and through Japanese immigration from the early 20(th) century, whereas HTLV-2 was only brought by immigrants through the Bering Strait. The endemicity of HTLV-2 among the indigenous people of Brazil makes the Brazilian Amazon the largest endemic area in the world for its occurrence. A review of HTLV-1 in all Brazilian tribes supports the African origin of HTLV-1 in Brazil. The risk of hyperendemicity in these epidemiologically closed populations and transmission to other populations reinforces the importance of public health interventions for HTLV control, including the recognition of the infection among reportable diseases and events.
Palavras-chave
HTLV-1, HTLV-2, Indians, Origin, Americas
URI
https://observatorio.fm.usp.br/handle/OPI/9640
Referências
  1. Alcantara LC, 2003, JAIDS-J ACQ IMM DEF, V33, P536
  2. Alcantara LCJ, 2003, AIDS RES HUM RETROV, V19, P519, DOI 10.1089/088922203766774577
  3. Alva IE, 2012, AM J TROP MED HYG, V87, P954, DOI 10.4269/ajtmh.2012.12-0289
  4. Andonov A, 2012, INFECT GENET EVOL, V12, P1822, DOI 10.1016/j.meegid.2012.07.015
  5. [Anonymous], 2013, AB PEOPL CAN 1 NAT P
  6. Arango C, 1999, J ACQ IMMUN DEF SYND, V20, P102
  7. Araujo A, 2004, ANN NEUROL, V56, P10, DOI 10.1002/ana.20126
  8. Barreto SM, 2012, INT J EPIDEMIOL, V41, P557, DOI 10.1093/ije/dys017
  9. Beilke MA, 2004, CLIN OUTCOMES DIS PR, V39, P253
  10. Biggar RJ, 1996, VIROLOGY, V216, P165, DOI 10.1006/viro.1996.0043
  11. Biglione M, 1999, AIDS RES HUM RETROV, V15, P407, DOI 10.1089/088922299311150
  12. Biglione MM, 2013, ATUALIZACIONES SIDA, V21, P84
  13. BLACK FL, 1994, AIDS RES HUM RETROV, V10, P1165, DOI 10.1089/aid.1994.10.1165
  14. Blas MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073978
  15. BOUZAS MB, 1994, AIDS RES HUM RETROV, V10, P1567, DOI 10.1089/aid.1994.10.1567
  16. Brasil. Ministerio da Saude, 2004, PROGR NAC DST AIDS G
  17. Cabral MB, 1998, J ACQ IMMUN DEF SYND, V19, P548
  18. Callatini S, 2005, RETROVIROLOGY, V2, P30
  19. Cann AJ, 1996, FIELDS VIROLOGY, P1849
  20. Carneiro-Proietti Anna Bárbara F, 2002, Rev Soc Bras Med Trop, V35, P499, DOI 10.1590/S0037-86822002000500013
  21. Carneiro-Proietti ABF, 2002, J BIOMED SCI, V9, P587, DOI 10.1159/000067286
  22. Carneiro-Proietti ABF, 2006, REV PANAM SALUD PUBL, V19, P44, DOI 10.1590/S1020-49892006000100007
  23. CARTIER L, 1993, JPN J CANCER RES, V84, P1
  24. Casseb J, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000487
  25. Catalan-Soares BC, 2001, REV BRAS EPIDEMIOL, V4, P81, DOI 10.1590/S1415-790X2001000200003
  26. Caterino-de-Araujo A, 1994, EUR J EPIDEMIOL, V10, P165, DOI 10.1007/BF01730366
  27. Cavalli-Sforza LL, 1994, HIST GEOGRAPHY HUMAN
  28. Chang YB, 2014, J INFECT DIS, V209, P523, DOI 10.1093/infdis/jit497
  29. Cook LBM, 2014, J INFECT DIS, V209, P486, DOI 10.1093/infdis/jit558
  30. Costa CA, 2013, PLOS NEGLECT TROP D, V7, pe2272
  31. Covas DT, 2003, AIDS RES HUM RETROV, V19, P689, DOI 10.1089/088922203322280919
  32. DAVIDSON M, 1990, J INFECT DIS, V161, P359
  33. de The GD, 1993, AIDS RES HUM RETROV, V9, P3816
  34. Dekaban G A, 1994, Clin Diagn Virol, V2, P67, DOI 10.1016/0928-0197(94)90039-6
  35. Desrames A, 2011, RETROVIROLOGY, V8, pA90
  36. Dipierri JE, 1999, MEDICINA-BUENOS AIRE, V59, P717
  37. DUENASBARAJAS E, 1993, AM J TROP MED HYG, V49, P657
  38. DUENASBARAJAS E, 1992, AIDS RES HUM RETROV, V8, P1851, DOI 10.1089/aid.1992.8.1851
  39. Egea E, 2002, REV ACAD COLOMB CIEN, V26, P181
  40. EHRLICH GD, 1989, BLOOD, V74, P1658
  41. Eiraku N, 1996, J VIROL, V70, P1481
  42. Eirin ME, 2010, J MED VIROL, V82, P2116, DOI 10.1002/jmv.21834
  43. Etzel A, 2001, J ACQ IMMUN DEF SYND, V26, P185, DOI 10.1097/00126334-200102010-00015
  44. FEIGENBAUM F, 1994, TRANSFUSION, V34, P158, DOI 10.1046/j.1537-2995.1994.34294143946.x
  45. FERRER JF, 1993, VIROLOGY, V197, P576, DOI 10.1006/viro.1993.1631
  46. Ferrer JF, 1996, J INFECT DIS, V174, P944
  47. FUJIYAMA C, 1993, J INFECT DIS, V168, P1075
  48. Fujiyoshi T, 1999, AIDS RES HUM RETROV, V15, P1235, DOI 10.1089/088922299310124
  49. FUJIYOSHI F, 1995, INT J CANCER, V63, P510
  50. GABBAI AA, 1993, AM J TROP MED HYG, V49, P664
  51. Galvao-Castro B, 2009, GAZ MED BAHIA, V79, P3
  52. Gascoyne RD, 1996, LEUKEMIA, V10, P552
  53. GASMI M, 1994, AIDS RES HUM RETROV, V10, P1313, DOI 10.1089/aid.1994.10.1313
  54. GESSAIN A, 1993, J VIROL, V67, P1015
  55. GESSAIN A, 1994, AIDS RES HUM RETROV, V10, P103, DOI 10.1089/aid.1994.10.103
  56. GESSAIN A, 1995, P NATL ACAD SCI USA, V92, P4041, DOI 10.1073/pnas.92.9.4041
  57. Gessain A, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00388
  58. Gongora-Biachi RA, 1997, ARCH MED RES, V28, P555
  59. GOUBAU P, 1992, NATURE, V359, P201, DOI 10.1038/359201a0
  60. Goubau P, 1996, J ACQ IMMUN DEF SYND, V13, pS242, DOI 10.1097/00042560-199600001-00036
  61. Hall WW, 1996, J ACQ IMMUN DEF SYND, V13, P204
  62. Hino S, 2011, P JPN ACAD B-PHYS, V87, P152, DOI 10.2183/pjab.87.152
  63. HJELLE B, 1991, J INFECT DIS, V163, P435
  64. IBGE - Instituto Brasileiro de Geografia e Estatistica, 2010, CENS DEM 2010 CAR GE
  65. IJICHI S, 1993, JPN J CANCER RES, V84, P1215
  66. INOSTROZA J, 1991, SCAND J INFECT DIS, V23, P507, DOI 10.3109/00365549109075102
  67. International Work Group for Indigenous Affairs, 2013, IND WORLD 2013
  68. Ishak R, 1998, Rev Soc Bras Med Trop, V31, P193
  69. Ishak Ricardo, 2003, Cad Saude Publica, V19, P901
  70. Ishak R, 2001, Rev Soc Bras Med Trop, V34, P519, DOI 10.1590/S0037-86822001000600004
  71. ISHAK R, 1995, AIDS RES HUM RETROV, V11, P813, DOI 10.1089/aid.1995.11.813
  72. Ita F, 2014, INT J INFECT DIS, V19, P46, DOI 10.1016/j.ijid.2013.10.005
  73. Kanzaki LIB, 2007, ARCH MED RES, V38, P897, DOI 10.1016/j.arcmed.2007.05.002
  74. Kanzaki LIB, 2008, RETROVIROLOGY, V1, P15
  75. KAPLAN JE, 1993, J ACQ IMMUN DEF SYND, V6, P327
  76. Kashima S, 2006, AIDS RES HUM RETROV, V22, P953, DOI 10.1089/aid.2006.22.953
  77. Kazanji Mirdad, 2003, Cad Saude Publica, V19, P1227, DOI 10.1590/S0102-311X2003000500002
  78. KITAGAWA T, 1986, JAMA-J AM MED ASSOC, V256, P2342
  79. KOMURIAN F, 1991, J VIROL, V65, P3770
  80. LAIRMORE MD, 1990, P NATL ACAD SCI USA, V87, P8840, DOI 10.1073/pnas.87.22.8840
  81. LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084
  82. Leon-Ponte M, 1998, J ACQ IMMUN DEF SYND, V17, P458
  83. LeonPonte M, 1996, J ACQ IMMUN DEF SYND, V13, P281
  84. LEVINE PH, 1993, AIDS RES HUM RETROV, V9, P123, DOI 10.1089/aid.1993.9.123
  85. Li HC, 1999, NAT MED, V5, P1428
  86. Liu HF, 1996, J GEN VIROL, V77, P359, DOI 10.1099/0022-1317-77-2-359
  87. Lowis GW, 2002, ANN EPIDEMIOL, V12, P46, DOI 10.1016/S1047-2797(01)00231-9
  88. Lowis GW, 1999, NEUROEPIDEMIOLOGY, V18, P37, DOI 10.1159/000026194
  89. Mahieux R, 1998, J VIROL, V72, P10316
  90. MALONEY EM, 1992, J INFECT DIS, V166, P100
  91. Medeot S, 1999, AM J TROP MED HYG, V60, P623
  92. Menna-Barreto Marcio, 2005, Cad Saude Publica, V21, P1947, DOI 10.1590/S0102-311X2005000600045
  93. MIURA T, 1994, P NATL ACAD SCI USA, V91, P1124, DOI 10.1073/pnas.91.3.1124
  94. Montanheiro P, 2008, VIRUS RES, V135, P22, DOI 10.1016/j.virusres.2008.01.015
  95. Montenegro RA, 2006, LANCET, V367, P1859, DOI 10.1016/S0140-6736(06)68808-9
  96. Murphy EL, 2004, J INFECT DIS, V190, P504, DOI 10.1086/422398
  97. Murphy EL, 2004, EMERG INFECT DIS, V10, P109
  98. NAKAUCHI CM, 1992, REV I MED TROP, V34, P323, DOI 10.1590/S0036-46651992000400009
  99. NAKAUCHI CM, 1990, MEM I OSWALDO CRUZ, V85, P29
  100. NEEL JV, 1994, P NATL ACAD SCI USA, V91, P10737, DOI 10.1073/pnas.91.22.10737
  101. Novoa P, 1997, INT C HUM RETR HTLV
  102. OGER JJF, 1993, CAN J NEUROL SCI, V20, P302
  103. Ohkura S, 1999, J GEN VIROL, V80, P1995
  104. PARDI D, 1993, J VIROL, V67, P4659
  105. Perez GE, 1993, J ACQ IMMUN DEF SYND, V6, P1368
  106. Peters AA, 2000, AIDS RES HUM RETROV, V16, P883, DOI 10.1089/08892220050042828
  107. PICARD FJ, 1995, J VIROL, V69, P7248
  108. POWER C, 1989, CAN J NEUROL SCI, V16, P330
  109. Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968
  110. REEVES WC, 1990, AM J TROP MED HYG, V43, P410
  111. Reich DE, 1998, P NATL ACAD SCI USA, V95, P8119, DOI 10.1073/pnas.95.14.8119
  112. Robinson J, 2001, NUCLEIC ACIDS RES, V29, P210, DOI 10.1093/nar/29.1.210
  113. Roucoux DF, 2004, AIDS REV, V6, P144
  114. Salemi M, 1999, GENE, V234, P11, DOI 10.1016/S0378-1119(99)00169-9
  115. Salemi M, 1998, VIROLOGY, V246, P277, DOI 10.1006/viro.1998.9215
  116. Sanchez-Palacios C., 2003, International Journal of Infectious Diseases, V7, P132, DOI 10.1016/S1201-9712(03)90009-9
  117. Segurado AAC, 2002, MEM I OSWALDO CRUZ, V97, P329, DOI 10.1590/S0074-02762002000300009
  118. Shindo N, 2002, AIDS RES HUM RETROV, V18, P71, DOI 10.1089/088922202753394736
  119. Sonoda S, 2011, CANCER SCI, V102, P295, DOI 10.1111/j.1349-7006.2010.01820.x
  120. SWITZER WM, 1995, J VIROL, V69, P621
  121. Talarmin A, 1999, J GEN VIROL, V80, P3083
  122. Abdulla MA, 2009, SCIENCE, V326, P1541, DOI 10.1126/science.1177074
  123. Toro C, 2005, J CLIN VIROL, V33, P65, DOI 10.1016/j.jcv.2004.10.004
  124. Vallinoto ACR, 2002, HUM BIOL, V74, P633, DOI 10.1353/hub.2002.0059
  125. Vallinoto ACR, 1998, MEM I OSWALDO CRUZ, V93, P407, DOI 10.1590/S0074-02761998000300026
  126. Vallinoto ACR, 2004, JPN J INFECT DIS, V57, P156
  127. VANDAMME AM, 1994, VIROLOGY, V202, P212, DOI 10.1006/viro.1994.1337
  128. Van Dooren S, 1998, J GEN VIROL, V79, P2695
  129. Van Dooren S, 2004, MOL BIOL EVOL, V21, P603, DOI 10.1093/molbev/msh053
  130. Visona K, 1997, INT C HUM RETR HTLV
  131. VITEK CR, 1995, J INFECT DIS, V171, P1022
  132. Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102
  133. Yamashita M, 1998, J MED VIROL, V55, P152, DOI 10.1002/(SICI)1096-9071(199806)55:2<152::AID-JMV12>3.0.CO;2-K
  134. YANAGIHARA R, 1991, LANCET, V337, P617, DOI 10.1016/0140-6736(91)91684-M
  135. ZAMORA T, 1990, JPN J CANCER RES, V81, P715
  136. ZANINOVIC V, 1994, AIDS RES HUM RETROV, V10, P97, DOI 10.1089/aid.1994.10.97
  137. ZELLA D, 1990, LANCET, V336, P575, DOI 10.1016/0140-6736(90)92140-D
  138. Zihlmann KF, 2013, J INFECT DIS THER, V1
  139. Zihlmann KF, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001705

Coleções
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/56